![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FRRS1 |
Gene summary for FRRS1 |
![]() |
Gene information | Species | Human | Gene symbol | FRRS1 | Gene ID | 391059 |
Gene name | ferric chelate reductase 1 | |
Gene Alias | SDFR2 | |
Cytomap | 1p21.2 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | Q6ZNA5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
391059 | FRRS1 | CCI_1 | Human | Cervix | CC | 1.96e-04 | 6.46e-01 | 0.528 |
391059 | FRRS1 | CCI_2 | Human | Cervix | CC | 4.04e-03 | 5.05e-01 | 0.5249 |
391059 | FRRS1 | CCI_3 | Human | Cervix | CC | 2.31e-14 | 6.73e-01 | 0.516 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Cervix | ![]() | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00550726 | Cervix | CC | iron ion homeostasis | 19/2311 | 85/18723 | 6.88e-03 | 3.74e-02 | 19 |
GO:00550768 | Cervix | CC | transition metal ion homeostasis | 27/2311 | 138/18723 | 9.89e-03 | 4.85e-02 | 27 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FRRS1 | SNV | Missense_Mutation | novel | c.945N>T | p.Lys315Asn | p.K315N | Q6ZNA5 | protein_coding | tolerated(0.05) | possibly_damaging(0.463) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FRRS1 | insertion | Nonsense_Mutation | novel | c.527_528insTTCTCTATGCACTTTGCCACACAAAATACACAGAACCACAATTTCCTTTTACAACACCTAAAGCTAC | p.Val177SerfsTer20 | p.V177Sfs*20 | Q6ZNA5 | protein_coding | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD | ||
FRRS1 | insertion | Frame_Shift_Ins | novel | c.370_371insA | p.Thr124AsnfsTer4 | p.T124Nfs*4 | Q6ZNA5 | protein_coding | TCGA-BS-A0TJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
FRRS1 | insertion | Frame_Shift_Ins | novel | c.370_371insA | p.Thr124AsnfsTer4 | p.T124Nfs*4 | Q6ZNA5 | protein_coding | TCGA-D1-A174-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
FRRS1 | insertion | Frame_Shift_Ins | novel | c.370dupA | p.Thr124AsnfsTer4 | p.T124Nfs*4 | Q6ZNA5 | protein_coding | TCGA-E6-A2P9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
FRRS1 | SNV | Missense_Mutation | c.1781A>T | p.Gln594Leu | p.Q594L | Q6ZNA5 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-ED-A459-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Ancillary | alvesin | CR | |
FRRS1 | insertion | Frame_Shift_Ins | novel | c.69_70insT | p.Pro24SerfsTer15 | p.P24Sfs*15 | Q6ZNA5 | protein_coding | TCGA-KR-A7K0-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
FRRS1 | SNV | Missense_Mutation | novel | c.1613N>A | p.Met538Lys | p.M538K | Q6ZNA5 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
FRRS1 | SNV | Missense_Mutation | c.551C>T | p.Pro184Leu | p.P184L | Q6ZNA5 | protein_coding | tolerated(0.4) | benign(0.015) | TCGA-44-7660-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Vaccine | recprame+as15 | PD | |
FRRS1 | SNV | Missense_Mutation | c.1248N>T | p.Met416Ile | p.M416I | Q6ZNA5 | protein_coding | tolerated(0.49) | benign(0.007) | TCGA-44-7670-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |